FDA expands label for Novartis and Roche's blockbuster, converts EMD Serono's NSCLC drug to full approval
The FDA on Friday signed off on an expanded label for Novartis and Roche’s blockbuster Xolair (omalizumab) and on Thursday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
